Carmelo Roco, MD
Internal Medicine · San Francisco, CANPI 1316996465
Payments from drug & device makers
Across 655 payments — averaging $23.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$5K
- GSK$2K
- Boehringer Ingelheim$939
- AstraZeneca$898
- Novo Nordisk$826
- Kowa Pharmaceuticals America, Inc.$628
- plus $6K from 32 others
What the payments were for
- Food & beverage$14,79098%
- Education$2892%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 157 | $4,594 |
| GSK | 60 | $1,668 |
| Boehringer Ingelheim | 43 | $939 |
| AstraZeneca | 37 | $898 |
| Novo Nordisk | 43 | $826 |
| Kowa Pharmaceuticals America, Inc. | 42 | $628 |
| AbbVie(2 entities) | 37 | $548 |
| Merck | 25 | $455 |
| Pfizer | 26 | $433 |
| Merz North America, Inc. | 9 | $429 |
| Amarin Pharma, Inc. | 23 | $418 |
| Ironwood Pharmaceuticals, Inc | 28 | $394 |
| Lilly USA, LLC | 17 | $390 |
| Astellas Pharma US Inc | 8 | $363 |
| Amgen | 17 | $341 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $260 |
| Novartis | 13 | $224 |
| Neurocrine Biosciences, Inc. | 3 | $208 |
| Sanofi-aventis U.S. LLC | 10 | $184 |
| Organogenesis Inc. | 1 | $125 |
| Sumitomo Pharma America, Inc. | 8 | $110 |
| Arbor Pharmaceuticals, Inc. | 7 | $109 |
| E.r. Squibb & Sons, L.L.C. | 4 | $78 |
| Mimedx Group, Inc. | 1 | $71 |
| Otsuka America Pharmaceutical, Inc. | 3 | $56 |
| Sunovion Pharmaceuticals Inc. | 2 | $51 |
| Hikma Pharmaceuticals USA | 2 | $35 |
| Abbott | 1 | $32 |
| UCB, Inc. | 1 | $32 |
| Bayer | 1 | $30 |
| Eisai Inc. | 1 | $25 |
| Gilead | 1 | $21 |
| Dexcom, Inc. | 1 | $20 |
| Scilex Pharmaceuticals Inc. | 1 | $19 |
| Insulet Corporation | 1 | $19 |
| Forte Bio-pharma LLC | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Vifor Pharma, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,079 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 73 | $100,885 |
| JardianceEmpagliflozin | 75 | $77,944 |
| RybelsusSemaglutide | 21 | $42,973 |
| EliquisApixaban | 50 | $35,789 |
| FarxigaDapagliflozin Propanediol | 30 | $34,736 |
| JulucaDolutegravir/Rilpivirine | 30 | $25,314 |
| CreonLipase/Protease/Amylase | 22 | $22,604 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $22,579 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 25 | $20,773 |
| TradjentaLinagliptin | 26 | $16,950 |
| VascepaIcosapent Ethyl | 28 | $16,134 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 22 | $12,868 |
| Midodrine Hcl | 67 | $12,585 |
| Colesevelam Hcl | 11 | $9,448 |
| ZonisadeZonisamide | 12 | $4,704 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $4,594 | $100,88573 claims |
| Boehringer IngelheimJardiance, Tradjenta | $939 | $94,894101 claims |
| Novo NordiskRybelsus | $826 | $42,97321 claims |
| PfizerEliquis | $433 | $35,78950 claims |
| AstraZenecaFarxiga | $898 | $34,73630 claims |
| AbbVieCreon | $548 | $22,60422 claims |
| GSKTrelegy Ellipta | $1,668 | $22,57932 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in San Francisco
- Rahul AggarwalSan Francisco$24M
- Thomas MartinSan Francisco$13.7M
- Peter HuntSan Francisco$9.8M
- Diane HavlirSan Francisco$8.4M
- Sandy WongSan Francisco$6.6M
- Nina ShahSan Francisco$5.4M
- Katy TsaiSan Francisco$3.8M
- Riley BoveSan Francisco$3.6M
- Jacob LalezariSan Francisco$3.3M
- Flavio VincentiSan Francisco$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.